Left ventricular assist devices (LVADs) are increasingly being used as a bridge to heart transplantation or destination therapy. It is unclear which antithrombotic regimen should be used to reduce the risk of stroke. We systematically reviewed the literature on all types of antithrombotic regimens and stroke in patients with any type of LVADs. Our primary outcome measure was the mean incidence of any type of stroke. Twenty-six articles were selected as relevant, comprehending 1989 patients with a mean LVAD support of 200 days (range 30-621). The mean proportion of patients affected with stroke was 20% (range 0-55%), with a mean incidence of 0.74 (range 0-6.91) events/patient-year. Support with HeartMate II and a regimen of postoperative heparin converted to coumarins, acetylsalicylic acid (ASA) and dipyridamole resulted in 0.17 (mean; range 0.06-0.29) strokes/patient-year. HeartMate II support and the same regime without heparin was associated with 0.07 (mean; range 0.03-0.11) strokes/patient-year. A Novacor device with heparin, converted to coumarins, was associated with 3.82 (mean; range 1.03-6.91) strokes/patient-year, while ASA added to this regime resulted in 0.97 ischaemic strokes/patient-year (mean; range 0.53-1.48). Other combinations of assist devices and antithrombotic regimes were investigated in one or two studies only. This systematic review provides risk estimates for stroke for various LVADs and antithrombotic regimes. Our findings indicate that the postoperative use of heparin in HeartMate II patients is doubtful, and suggest an important role for antiplatelet drugs to prevent stroke in patients supported with a Novacor device.
INTRODUCTION
The number of patients with end-stage heart failure in need of heart transplantation is increasing, but this treatment is limited by a shortage of donor organs. Consequently, an increasing number of patients are supported by a ventricular assist device (VAD) [1] . These devices can also be used as a bridge to recovery of the native heart or as destination therapy for permanent support with better outcomes than optimal medical therapy [2, 3] .
Despite improvements in device technology, severe complications such as stroke still endanger the outcome of patients with a left VAD (LVAD) [4] . Aggressive antithrombotic therapy to prevent ischaemic stroke increases the risk of both systemic bleeding complications and haemorrhagic stroke. The present protocols on antithrombotic regimens are mainly based on animal experiments and expert opinion. Consequently, there is no consensus on antithrombotic therapy, and different protocols are currently being used.
The aim of this systematic review was to estimate the risk of stroke in patients with different types of LVADs and various antithrombotic regimes.
MATERIALS AND METHODS

Search strategy
A systematic search in the Pubmed and Embase databases was performed on 28 September 2011. The search terms for the domain, determinant and outcome were combined with Boolean terms 'AND' and 'OR' and limited to Title/Abstract (Table 1) .
We included references with a full text available, written in English, Dutch, German or French, and describe patients supported with one type of LVAD and a uniform anticoagulation protocol and provide information on the incidence of stroke as an outcome. All resulting articles were imported in RefWorks. All types of antithrombotic drugs applied to prevent thromboembolism were included. Our search terms were based on the pharmacological function of the medicaments, such as anticoagulation and antiplatelet effects. Our primary outcome measure was defined as any type of stroke including transient ischaemic attack (TIA). We included all MesH terms associated with stroke or TIA in our search strategy, also including 'death' and 'mort*'.
Selection of studies
Two authors (D.B. and A.L.D.) screened all titles and abstracts and excluded publications on other devices than LVADs, as well as animal studies, in vitro studies and case reports. The remaining publications were available for full critical appraisal. In this phase, articles that did not describe patients supported with one type of LVAD as a domain, a uniform antithrombotic regimen as a determinant and stroke as an outcome were excluded. Citation indexing on the included studies was done to screen for relevant publications not found by our search syntax, following the same critical appraisal strategy.
In the case of disagreement between the two authors or when the relevance of an article was doubtful, references were evaluated by three authors (D.B., W.M.B. and A.J.C.S.) to reach consensus on inclusion for this systematic review.
Outcome measurements
Stroke was differentiated into ischaemic stroke, including TIA, and haemorrhagic stroke, i.e. intracerebral haemorrhage (ICH).
Antithrombotic protocols
We classified the antithrombotic drugs used in the different protocols in six categories: (i) heparin; (ii) low-molecular-weight heparin (LMWH); (iii) coumarins; (iv) acetylsalicylic acid (ASA); (v) dipyridamole; and (vi) clopidogrel.
Based on the retrieved articles, we then defined 10 different combinations of postoperative antithrombotic regimens: (i) heparin, subsequently converted to coumarins, ASA and dipyridamole; (ii) heparin converted to coumarins and ASA; (iii) coumarins with ASA and dipyridamole; (iv) ASA and dipyridamole; (v) heparin converted to ASA and dipyridamole or clopidogrel; (vi) heparin converted to coumarins; (vii) heparin converted to coumarins with ASA and clopidogrel; (viii) LMWH converted to antiplatelets; (ix) LMWH converted to antiplatelets (ASA and clopidogrel) with coumarins; (x) heparin converted to coumarins, ASA, dipyridamole and clopidogrel.
Statistical analysis
All data were extracted from the references and collected in a database (SPSS ® 16.0). Continuous variables were presented as means with highest and lowest values (range). Categorical variables were presented as absolute numbers and percentages. The estimated risk of all types of stroke, ischaemic stroke and ICH, was calculated by dividing the total number of these events in a group of patients by the total follow-up in patient-years in that group, so that larger studies contributed more weight to the estimated risk than smaller investigations. Studies describing different antithrombotic protocols for subsets of patients were mentioned separately.
RESULTS
Literature selection
The literature search generated 433 hits in Pubmed and 798 hits in Embase. Duplicates were removed by RefWorks' function 'view duplicates'. A total of 838 references remained. After a manual review of the title, abstract and full text on the determinant, outcome and domain, 216 publications remained eligible for critical appraisal. After the critical appraisal, a total of 23 references were selected as relevant. Citation indexing on these relevant articles yielded three more relevant references (Fig. 1 ). 
TX & MCS
A total of 26 references were thus selected as relevant for this review: seven retrospective cohort studies (two multicentre and five single centre), 18 prospective cohort studies (three multicentre and 15 single-centre) and one multicentre randomized controlled trial (RCT).
Patient demographics
The selected literature described a total of 1989 patients with LVAD support between January 1988 and December 2008, with four studies with a partial overlap in the cohort of patients [5] [6] [7] [8] . The majority of patients (87%) underwent LVAD implantation as a bridge to transplantation. The mean age was 49 years (range 17-79) and the mean duration of support 200 days (range 30-621) ( Table 2 ).
The risk of stroke stratified for the type of LVAD The mean proportion of patients affected with any type of stroke was 20% (range 0-55%), with a mean incidence of 0.74 (range 0-6.91) events/patient-year, as shown in Table 3 The risk of stroke stratified for the type of LVAD and antithrombotic regimen Table 4 shows the risk of stroke according to the type of LVAD and antithrombotic regimen, which is discussed in more detail below.
HeartMate I Pneumatic LVAD ( pulsatile)
A total of 37 patients supported with the HeartMate I Pneumatic LVAD were described in two studies.
Twelve patients supported with a mean duration of 117 days used an antithrombotic regimen that consisted of postoperative heparin, subsequently converted to ASA and dipyridamole. No stroke occurred in these patients [9] .
In a study of 25 patients supported for a mean duration of 63 days, a regimen of high-dose ASA (350 mg daily) and dipyridamole (75 mg three times daily) was used. Ten of these 25 patients had to stop antiplatelet therapy because of side effects such as peptic-ulcer disease. One ICH occurred shortly postoperatively (0.23 events/patient-year) but no ischaemic stroke occurred [10] .
HeartMate I Vented Electric LVAD ( pulsatile)
One-hundred and thirty-eight patients supported with the HeartMate I Vented Electric LVAD were described in three studies. One RCT compared the clinical outcome of patients supported with this pulsatile-flow device (66 patients) with patients with the continuous-flow HeartMate II LVAD (134 patients) [7] . The 66 patients supported with the HeartMate I Vented Electric LVAD used heparin postoperatively, aiming for a partial thromboplastin time (PTT) between 45-50 s on the first postoperative day and 55-65 s thereafter, and ASA (81 mg daily) and dipyridamole (75 mg three times daily) subsequently. The incidence of stroke was 0.51 events/patient-year during a mean support time of 219 days.
In another study on 21 patients with a mean duration of support of 531 days, no stroke occurred with the treatment with ASA (81 or 325 mg daily) and clopidogrel (75 mg daily) [11] . In a third study that used a regimen of antiplatelets only (ASA 325 mg daily) in 51 patients supported for a mean duration of 140 days, only one stroke occurred resulting in an incidence of 0.05 events/patient-year [12] .
Novacor LVAS (pulsatile)
The Novacor LVAS was described in seven studies with a total of 600 patients. Three studies used an antithrombotic regimen consisting of postoperative heparin converted to coumarins and ASA (80-350 mg daily). The first study compared the outcome between patients with two types of inflow cannulae [13] . With technical improvement, there was a significant decrease in the frequency of stroke (from 21 to 12%, P = 0.01). The second study described a cohort of 18 patients with a mean support of 76 days, aiming at a PTT of 1.5-2.0 and an international normalized ratio (INR) of 2.5-3.5, and observed 0.53 strokes/patient-year [14] .
The third study evaluated high-dose antiplatelets (ASA 330 mg daily and dipyridamole 75 mg daily) added to a regimen consisting of postoperative heparin converted to coumarins [15] . They aimed for a PTT between 60 and 80 s and a target INR of 3.0-4.0. There was a slight, but statistically significant decrease in stroke incidence in the group of patients allocated to additional antiplatelets.
In a study on six patients supported for a mean duration of 30 days, the incidence of stroke was 20.6 events/patient-year with heparin postoperatively (target PTT 60-80 s) converted to coumarins (target INR between 2.5 and 4.0) [16] .
Thoratec LVAD ( pulsatile)
Twenty-four patients supported for a mean duration of 96 days were treated with postoperative heparin which was converted to coumarins with an aimed PTT of 1.5-2.0 and a target INR of 2.0-3.0 [17] . After the onset of TIA, these patients were additionally treated with ASA 150 mg daily. The stroke incidence in this group was 1.43 events/patient-year.
Jarvik-2000 LVAD (continuous)
This device was investigated in two studies, totalling 25 patients with a mean support duration of 261 days [18, 19] . In 7 of these 25 patients, the outflow cannula was sewn onto the descending aorta. The estimated stroke risk with this device was 0.34 events/ patient-year, with a notable high estimated risk of ICH of 0.22 events/patient-year. In the largest study on 22 patients, the incidence of stroke was 0.30 events/patient-year with an incidence of ICH of 0.24 events/patient-year (Table 4) .
Berlin Heart Incor (continuous)
In three studies, totalling 41 patients with a mean support duration of 157 days, the estimated stroke risk was 0.74 events/ patient-year. Fourteen patients were treated with LMWH and antiplatelets postoperatively and supported for a mean duration 170 days [20] . The stroke incidence in this subgroup was 0.92 events/patient-year.
Twelve patients with a mean support duration of 305 days used postoperative heparin, subsequently converted to ICH: intracerebral haemorrhage; n.m.: not mentioned; ASA: acetylsalicylic acid; LMWH: low-molecular-weight heparin; HMI VE: HeartMate I Vented Electric; HM I PN: HeartMate I Pneumatic; Incor: Berlin Incor; DeBakey: MicroMed DeBakey. The mean support days if not reported were calculated as: total duration of support/number of patients supported; incidence (patient-years) = events × 365/total support days. The bold text indicates the total estimated risk of stroke specified for VADs and anticoagulation regimen. coumarins, ASA and clopidogrel [21] . The aim of this regimen was an aPTT 60-80 s and a target INR of 2.8-3.2. The estimated stroke risk was 0.61 events/patient-year. Fifteen other patients were treated according to the same regimen, but the PTT was aimed at between 60 and 80 s and a target INR of 2.5-4.0 [22] . Twenty-seven percent of these patients suffered a stroke, with a stroke incidence of 0.64 events/patient-year.
TX & MCS
MicroMed DeBakey VAD (continuous)
Two studies, totalling 41 patients with a mean duration of support of 115 days, showed an estimated stroke risk of 0.85 events/patient-year.
Thirty-two patients were treated postoperatively with heparin, converted to coumarins, ASA and clopidogrel [23] . They were supported for a mean duration of 47 days. The stroke incidence was 0.58 events/patient-year with a notable high incidence of ICH (0.39 events/patient-year).
The second study combined two levels of anticoagulation, but found no decrease in the incidence of stroke, with 1.01 events/ patient-year in the first protocol, compared with 1.05 events/ patient-year in the second protocol (Table 4) .
HeartMate II LVAD (continuous)
The HeartMate II LVAD was described in eight studies with a total of 1083 patients. Six studies with a total of 905 patients supported for a mean duration of 277 days (range 155-621) used a protocol consisting of postoperative heparin converted to coumarins, ASA and dipyridamole [5-8, 24, 25] . ASA was dosed at between 81 and 325 mg daily and dipyridamole was dosed at 75 mg one to three times daily. Five of these studies aimed for a PTT between 45-50 s on the first postoperative day and 55-65 s on the third postoperative day and a target INR between 2.0 and 3.0 [5-7, 24, 25] . The estimated stroke risk in these studies was 0.25 events/patient-year. The sixth study compared three groups of patients, in which Group A (134 patients) received therapeutic heparin with a PTT above 55 s, Group B (118 patients) subtherapeutic heparin with a PTT of 40-55 s and Group C (122 patients) received no heparin. All three groups were subsequently converted to an antithrombotic regimen consisting of coumarins, ASA (81-325 mg daily) and dipyridamole (75 mg three times a day) [8] . There was no significant difference in stroke risk during a mean LVAD support of 293 days between the three groups.
Forty-five patients (mean follow-up 238 days) used postoperative heparin which was converted to coumarins and ASA 81 mg daily [26] . They aimed for a PTT between 45 and 50 s on postoperative Day 1 to a PTT between 55 and 65 s on postoperative Day 3 and a target INR between 2.0 and 3.0. Because of recurrent gastrointestinal bleeding in the first patients, they decided to stop postoperative heparin and aimed for a target INR between 1.5 and 2.0. The incidence of stroke in this group was 0.03 events/patient-year with no cases of ICH.
In 11 patients with a mean support duration of 214 days, postoperative LMWH and ASA were given instead of unfractionated heparin [27] . After the third postoperative day, LMWH was converted to coumarins and clopidogrel was added. The stroke incidence in this group was 0.31 events/patient-year with no ICH.
The onset of stroke in relation to the duration of HeartMate II LVAD support was examined in three studies, with partly the same patient population [5, 6, 8] . Adverse events were divided into early (0-30 days postoperative) and late (>30 days postoperative). Half of the ischaemic strokes (49%) occurred in the early postoperative period and the other half (51%) in the late postoperative period. The onset of ICH was 36% in the early postoperative period vs 55% in the late postoperative period.
DISCUSSION
This is the first systematic review on cerebrovascular complications of LVADs. We found that in patients with a HeartMate II device and an antithrombotic regime of coumarins, ASA and dipyridamole, the use of postoperative heparin seemed to increase the risk of stroke (0.17 vs 0.07 strokes/patient-year). Among patients with a Novacor device and an antithrombotic regime of heparin subsequently converted to coumarins, users of additional ASA seemed to have a lower risk of stroke (0.53 events/ patient-year) than patients who did not use ASA (3.82 strokes/ patient-year). Other combinations of LVADs and antithrombotic regimes were investigated in one or two studies only.
It should be noted that the risk estimates described above were averages of risks detected in different study populations. In addition, most studies did not describe risk factors for stroke such as diabetes mellitus, smoking behaviour or previous stroke. Because all patients had LVAD implantation without any concomitant valve surgery, risk estimates for this group of patients could not be given. Further, there were only few studies that provided information about the time of onset of stroke. Many of the selected studies were retrospective cohort studies that are often subject to bias.
The HeartMate II is currently the most frequently used VAD worldwide with more than 4000 implantations and a longest duration of support for over 5 years. The recommended antithrombotic regimen for the HeartMate II consists of coumarins (target INR 1.5-2.5) in combination with ASA. A previously used regimen that also included postoperative heparin that had to be converted to coumarins was mainly based on the experience with pump-thrombosis in the initial HeartMate II implants [25] . However, postoperative heparin seems not to decrease the number of thromboembolic events after HeartMate II implantation and may increase the risk of short-term systemic bleeding complications [8, 26] .
However, bleeding complications of LVAD support, such as intracranial haemorrhage, cannot solely be explained by the use of antithrombotics. Recent studies suggest that the rotary pump design of the last generation VADs may contribute to the onset of the acquired von Willebrand syndrome (AVWS) [28] [29] [30] [31] [32] [33] [34] . Large von Willebrand factor (vWF) multimers are supposed to be mechanically destructed under conditions of high shear stress. The ability of vWF to bind to collagen or the platelet receptor GP1b is impaired during VAD support, causing disturbance of the primary haemostasis, possibly contributing to bleeding complications [28, 29, 31, 32, 34, 35] . AVWS is reversible in many patients after VAD explantation, further supporting the hypothesis that this syndrome is induced by VAD support [28, [31] [32] [33] [34] . Future studies with larger populations are needed to investigate the role of AVWS in bleeding complications and a more adapted antithrombotic regimen may be needed based on these changes in the coagulation system to prevent thromboembolic and haemorrhagic events.
Most of the antithrombotic regimens described in this review used postoperative heparin. However, the use of unfractionated heparin comes with the risk of heparin-induced thrombocytopenia (HIT), a condition that presents most often within 5-10 days after cardiac surgery [36, 37] . HIT is an immune-mediated disorder in which immunoglobulin G is generated, which results in multimolecular complexes heparin, platelet factor 4 and immunoglobulin G. These complexes bind to platelet surfaces, resulting in platelet activation and initiation of coagulation. For this reason, unfractionated heparin might be avoided after VAD implantation or might be replaced by LMWHs or other antithrombotic agents including direct thrombin inhibitors such as argatroban, hirudin or bivalirudin [38, 39] . However, a major advantage of unfractionated heparin over LMWHs is the possibility of rapid and complete neutralization by protamine [40] . More research is needed to investigate the effect of antithrombotic agents such as LMWH and direct thrombin inhibitors in this group of patients.
SUMMARY
This is the first systematic review on cerebrovascular complications in patients with LVAD support. We provide estimates for the risk of stroke for various LVADs and antithrombotic regimes. Our findings indicate that the postoperative use of heparin in HeartMate II patients is doubtful, and suggest an important role for antiplatelet drugs to prevent stroke in patients supported with a Novacor LVAD.
